Medicine and Health Sciences Commons^™

Reducing Time To Antibiotics In Patients With Neutropenic Fever On A Bone Marrow Transplant Unit, Regina Mcguire, Christopher Anand Gardner, Jordan Villars, William O'Hara, Jessica Radicke, Felicia Rivera, Jill Cristiano, Joanne E. Filicko-O'Hara, Usama Gergis, Adam F. Binder

Student Papers, Posters & Projects

Background/Methods: Timely administration of antibiotics in patients with neutropenic fever (NF) is essential for reducing morbidity and mortality among oncology patients. The optimal time to antibiotics (TTA) for patients with NF is unclear, but IDSA/ASCO guidelines recommend a median TTA within one hour of documented fever. This study focused on identifying barriers at a single academic institution to timely antibiotic administration for patients admitted to the inpatient Bone Marrow Transplant (BMT) unit, and implemented new processes to reduce median TTA to less than 60 minutes.

Methods: Chart reviews were performed to identify causes for delays in antibiotics (abx). Based on …

Creating And Implementing A Principal Investigator Tool Kit For Enhancing Accrual To Late Phase Clinical Trials: Development And Usability Study., Kristin A Higgins, Alexandra Thomas, Nancy Soto, Rebecca Paulus, Thomas J George, Thomas B Julian, Sharon Hartson Stine, Merry Jennifer Markham, Maria Werner-Wasik

Kimmel Cancer Center Faculty Papers

BACKGROUND: Accrual to oncology clinical trials remains a challenge, particularly during the COVID-19 pandemic. For late phase clinical trials funded by the National Cancer Institute, the development of these research protocols is a resource-intensive process; however, mechanisms to optimize patient accrual after trial activation are underdeveloped across the National Clinical Trial Network (NCTN). Low patient accrual can lead to the premature closure of clinical trials and can ultimately delay the availability of new, potentially life-saving therapies in oncology.

OBJECTIVE: The purpose of this study is to formally create an easily implemented tool kit of resources for investigators of oncology clinical …

Telehealth Cancer-Related Fatigue Clinic Model For Cancer Survivors: A Pilot Randomised Controlled Trial Protocol (The T-Crf Trial), Rahul Ladwa, Elizabeth P. Pinkham, Laisa Teleni, Brigid Hanley, Gemma Lock, Jodie Nixon, Oluwaseyifunmi Andi Agbejule, Fiona Crawford-Williams, Lee Jones, Mark B. Pinkham, Jane Turner, Patsy Yates, Steven M. Mcphail, Joanne F. Aitken, Carmen P. Escalante, Nicolas H. Hart, Raymond J. Chan

Research outputs 2022 to 2026

INTRODUCTION: Cancer-related fatigue (CRF) is one of the most common and debilitating adverse effects of cancer and its treatment reported by cancer survivors. Physical activity, psychological interventions and management of concurrent symptoms have been shown to be effective in alleviating CRF. This pilot randomised controlled trial (RCT) will determine the feasibility of a telehealth CRF clinic intervention (T-CRF) to implement evidence-based strategies and assess the impact of the intervention on CRF and other clinical factors in comparison to usual care. METHODS AND ANALYSIS: A parallel-arm (intervention vs usual care) pilot RCT will be conducted at the Princess Alexandra Hospital in …

Crizotinib In Patients With Tumors Harboring Alk Or Ros1 Rearrangements In The Nci-Match Trial., A S Mansfield, Z Wei, R Mehra, A T Shaw, C H Lieu, P M Forde, A E Drilon, Edith P. Mitchell, J J Wright, N Takebe, E Sharon, D Hovelson, S Tomlins, J Zeng, K Poorman, N Malik, R J Gray, S Li, L M Mcshane, L V Rubinstein, D Patton, P M Williams, S R Hamilton, B A Conley, C L Arteaga, L N Harris, P J O'Dwyer, A P Chen, K T Flaherty

Department of Medical Oncology Faculty Papers

The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and G were developed to evaluate the role of crizotinib in rare tumors that harbored either ALK or ROS1 rearrangements. Patients with malignancies that progressed following at least one prior systemic therapy were accrued to the NCI-MATCH for molecular profiling, and those with actionable ALK or ROS1 rearrangements were offered participation in sub-protocols F or G, respectively. There were five patients who enrolled on Arm F (ALK) and four patients on Arm G (ROS1). Few grade 3 or 4 toxicities were noted, …

Adverse Events Reporting Of Clinical Trials In Exercise Oncology Research (Advance): Protocol For A Scoping Review, Hao Luo, Oliver Schumacher, Daniel A. Galvão, Robert U. Newton, Dennis R. Taaffe

Research outputs 2022 to 2026

Introduction: Adequate, transparent, and consistent reporting of adverse events (AEs) in exercise oncology trials is critical to assess the safety of exercise interventions for people following a cancer diagnosis. However, there is little understanding of how AEs are reported in exercise oncology trials. Thus, we propose to conduct a scoping review to summarise and evaluate current practice of reporting of AEs in published exercise oncology trials with further exploration of factors associated with inadequate reporting of AEs. The study findings will serve to inform the need for future research on standardisation of the definition, collection, and reporting of AEs for …

Lymphoma With Tuberculous Granulomas, Jyoti Mohan Lal, Anila Rashid

Department of Pathology and Laboratory Medicine

Chronic granulomatous inflammation is a common finding in lymphoproliferative disorders (LPDs), but it is important to exclude coexisting mycobacterium tuberculosis (MTB) especially in patients from areas of high endemicity. This case emphasizes the relevance of performing MTB culture on bone marrow exhibiting LPD and concomitant granulomas